Roivant Sciences Income Statement
ROIV / Health Care|6 years of annual SEC 10-K data (FY2020-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 6 fiscal years. All figures from audited SEC 10-K filings.
Roivant Sciences reported $33M in revenue and $4.3B in net income for FY2025. Revenue has grown at a 6.6% compound annual rate over the past 5 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $32.7M | $29.1M | $32.7M | $23.8M | $55.3M | $23.8M |
| SG&A Expense | $416.1M | $591.4M | $687.4M | $259.9M | $775.0M | $259.9M |
| R&D Expense | $439.9M | $550.4M | $439.9M | $236.6M | $483.0M | $236.6M |
| Operating Income | $4.5B | -$1.0B | $4.5B | -$1.1B | -$1.4B | -$1.1B |
| Interest Expense | - | - | $34.8M | $2.8M | $7.0M | $2.8M |
| Income Tax | $21.5M | $48.2M | $21.5M | $1.7M | $369.0K | $1.7M |
| Net Income | $4.3B | -$172.0M | $4.3B | -$809.2M | -$845.3M | -$809.2M |
| EPS (Basic) | $5.55 | -$1.42 | -$1.42 | - | -$1.26 | - |
| EPS (Diluted) | $5.23 | -$1.42 | -$1.42 | -$1.28 | -$1.26 | - |
| Shares Outstanding | 695.9M | 806.7M | 760.1M | 651.6M | 669.8M | 630.0M |
| Operating Margin | 13746.9% | -3453.3% | 13746.9% | -4500.5% | - | - |
| Profit Margin | 13294.2% | -592.0% | 13294.2% | -3400.9% | - | - |